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Summary
Due to constant progress in oncology, survival rates of pa-
tients (children and adults) with cancer are increasing. Con-
sequently, the reproductive future of young cancer patients
needs to be addressed carefully. Fertility preservation tech-
niques are available and issues such as the time available
for fertility treatments, patients’ age, presence of a partner
and patients’ personal wishes have to be considered.
In Switzerland, a first therapeutic network (Réseau Ro-
mand de Cancer et Fertilité), was created in the French
speaking part of Switzerland in 2006. Since 2010, a global
Swiss network (FertiSave) has been created. The goal of
these networks is to maximise the safety and efficacy of
fertility preservation options offered to cancer patients
without compromising their oncological prognosis. Pa-
tients’ needs have to be identified, the therapeutic options
evaluated rapidly and the optimal treatment promptly im-
plemented in these urgent situations.
This article reviews the fertility preservation options cur-
rently available and makes recommendations for different
specific cancer situations, consistent with the latest sci-
entific evidence and in general agreement with internation-
al recommendations.
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Introduction
In adult male cancer patients, sperm cryopreservation be-
fore cytotoxic treatment has been offered and efficaciously
performed for several decades, even if it at times forgotten
when caught in the stress caused by the diagnosis and the
need for rapid initiation of treatment.
In women of reproductive age with cancer, there is also a
need to discuss the consequences of their treatments on fu-
ture fertility. The duration of amenorrhoe and risk of per-
manent failure greatly depend on the type of cancer and
treatment (table 1, adapted from [1]), as well as the pa-
tient’s age and specific susceptibility line. There is no dir-
ect comparison between women and men concerning the
strength of effect of the different substances or regimen.
However, the same classes of drugs seem to be equally tox-
ic in men and women (i.e. alkylants).
The inherent complexity of this emerging field has required
establishing a multidisciplinary approach, which guaran-
tees a better and safer management than individual initi-
atives might offer. In Switzerland, the first multidisciplin-
ary network of reproductive medicine specialists, gynae-
cologic/medical/paediatric oncologists, radiotherapists and
psychologists (“Réseau Romand de Cancer et Fertilité,
RRCF”) was created in 2006 in the French Speaking part
of the country (1.7 million inhabitants). The RRCF com-
prises the two University hospitals, but also regional public
and private hospitals/infertility centres are invited to par-
ticipate on a voluntary basis and to record their patients
in the elaborated register. In practice, only patients of the
two University hospitals and public hospitals have been
recorded until now. The aims were to establish and co-
ordinate fertility preserving measures tailored to the cancer
type, personal characteristics and treatment envisioned [2].
Since inception, every counselling and fertility preserva-
tion measure offered by RRCF was codified in an elab-
orated register that documents the indication, diagnosis,
planned oncologic treatment and fertility preservation
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measure implemented or on the contrary, the patient’s de-
cline of such offers. To this date, 85 patients were handled
in an emergency setting that offered a thorough evaluation
and discussion conducted by a dedicated multidisciplinary
task force with one or several consultations for discussing
fertility preservation options with reproductive medicine
specialists. From these 85 patients, 61% had a treatment
(forty patients had controlled ovarian hyperstimulation
with cryopreservation of gametes and/or pre-embryos and
12 patients had cryopreservation of ovarian tissue). A ded-
icated psychological counselling [3] has been routinely
offered because of the stressful context: The shock caused
by the diagnosis of cancer, the treatments envisaged, the
fragility of life with the idea of possible death and, in the
event of recovery, the risk of future infertility. All these
concerns come together and need urgent decisions. The af-
fected patients are not prepared and counselling is of para-
mount importance. The sources of stress that arise from
cancer and fertility issues are multiple. First, Assisted Re-
productive Technologies (ART) do not guarantee preg-
nancy after cancer. The patient is also not even certain of
ever using the saved gametes or (pre-) embryos because
fecundity may spontaneously occur, or she may elect not to
conceive. Second, because ART is self paid in Switzerland
as in many other countries, the costs of the emergency ART
have to be assumed by the patient herself.
While other publications exist on fertility preservation net-
works [4], the present article’s originality stands in the
collective process of its undertaking that included all the
parties at stake. Moreover, as other publications [4] schem-
atised 3 oncologic situations only (breast cancer, borderline
ovarian tumours and Hodgkin’s Lymphoma, the present
article includes larger arrays of oncologic pathologies (tu-
mour types and clinical situations) in the discussion (i.e.
different ovarian cancers, cervical cancer, endometrial can-
cer, leukaemia and paediatric oncologic situations).
The fertility preservation options are discussed, making
practical recommendations in accordance with the latest
scientific findings.
General remarks
All cancer patients of reproductive age (or younger) must
be informed about fertility issues associated with their can-
cer and foreseen treatments. Fertility preservation is gen-
erally considered only in women under 40 years of age.
Ovarian function is evaluated by a reproductive medicine
specialist prior to fertility preservation measuring the anti-
mullerian hormone (AMH) and antral follicle count (AFC).
It is recommended to repeat AMH measurement one year
after chemotherapy in order to assess the net follicular loss
due to chemotherapy and to estimate ovarian function.
As certain chemotherapeutic agents may cause some car-
diovascular complications, as for example adriamycin de-
rivatives, follow-up of pregnancies is recommended in spe-
cialised centres.
Data on the risk of malformations or childhood malignan-
cies in offspring of cancer survivors are however reassur-
ing [5].
For better risk assessment and quality control, a register of
all fertility preservation measures and techniques, includ-
ing outcomes and complications, is of the outmost import-
ance. The primary objective that should guide all fertil-
ity preservation counselling is to assure that any measure
offered is not bound to harm by reducing the efficacy of
cancer treatment. Moreover, the proposed options should
not undermine the spontaneous pregnancy chances when
these exist. In particular, any offer of fertility preservation
measure that amounts to removing some gonadal tissue, as
done for ovarian tissue cryopreservation, should be envi-
sioned with due care and as little tissue as possible has to be
cryopreserved. Generally speaking such measures should
be avoided when natural pregnancy chances are real, as in
the case of breast cancer, for the fear that the removal of
gonadal tissue might harm natural pregnancy chances.
Techniques of fertility preservation
Sperm cryopreservation
Sperm can be cryopreserved in post pubertal men if sper-
matozoa are present in the ejaculate. Depending on several
factors, artificial insemination, In-Vitro Fertilization (IVF)
or Intracytoplasmatic Sperm Injection (ICSI) can be under-
taken after recovery.
Cryopreservation of testicular tissue
When no spermatozoa are found in the ejaculate, testicular
sperm extraction (TESE) and cryopreservation of testicular
tissue can be offered, if the time frame (1 day) allows it.
TESE-ICSI can be offered after recovery.
Table 1: Gonadotoxicity of chemotherapeutic agents.
High gonadotoxic potential Moderate gonadotoxic potential Mild or no gonadotoxic potential
Cyclophosphamide Cisplatin with low cumulative dose Bleomycin
Chlorambucil Carboplatin with low cumulative dose Actinomycin D
Melphalan Adriamycin (Doxorubicin) Vincristine
Busulphan Etoposide Methotrexate
Nitrogen Mustard 5-Fluoro-uracil
Procarbazine Mercaptopurine
Dacarbazine Treatment protocols for Hodgkin lymphoma without
alkylating agents.
Ifosfamide Prednisone
Thiotepa Interpheron-alpha
Carmustine
Lomustine
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ART with cryopreservation of unfertilised oocytes and/
or (pre-) embryos
IVF/ICSI and cryopreservation of unfertilised oocytes and/
or (pre-) embryos are offered worldwide. However, the
Swiss Law for ART forbids the cryopreservation of cleav-
ing stage embryos [6].
These techniques are applicable in post pubertal women. At
least two weeks are required for implementing such meas-
ures before initiating the oncologic treatment. A hormon-
al stimulation of the ovaries is necessary for harvesting a
maximum of oocytes, while avoiding the risk of ovarian
hyperstimulation syndrome (OHSS). Several stimulation
protocols exist. A special protocol for breast cancer (BC)
has been developed that reduces estradiol levels within
menstrual cycle limits, without compromising the oocyte
crop [7, 8]. ICSI is generally applied in order to minimise
the risk of fertilisation failure. If the patient has no partner
or is unsure about her marital plans, it is better to cryop-
reserve unfertilised oocytes rather than (pre-) embryos. If
the couple has already decided to start a family or has chil-
dren together, (pre-) embryos (belonging to both partners,)
are cryopreserved. In certain cases, a split option (with both
oocytes and (pre-) embryos) is chosen.
Treatment costs have to be discussed with the patient, as
IVF-ICSI is relatively expensive (Swiss Francs (CHF)
6,000–9,000) and not covered by the Swiss health insur-
ance. After the cancer treatment, there can be additional
costs (CHF 1,500–2,000 per cryocycle). Moreover, most
centres have yearly fees for the cryopreservation (CHF
200–300 per year).
Risks, complications and success
Complications during or following IVF-ICSI treatments
are very rare: oocyte pick-up (<1‰), OHSS (<1%), insuf-
ficient ovarian response (<5%).
Success depends on numerous factors. Pregnancy rates are
higher with cryopreserved (pre-) embryos compared to un-
fertilised oocytes (implantation rate of one oocyte or (pre-)
embryo being 10–15% or 6–8% [9], respectively).
Ovarian tissue cryopreservation (OTC)
This method consists in removal of ovarian tissue by lap-
aroscopy or laparotomy. The amount of the ovarian tissue
removed has varied according to the different practices
with no consensus as of yet on the best measures. Gener-
ally, the amount depends on the expected ovarian damage.
There are theoretically two options of further utilisation
after OTC:
1. Ortho-/heterotopic transplantation
2. In-vitro maturation (IVM) of primordial follicles (not yet
accomplished in humans).
The main advantage of the second option is that there is
no risk of re-introduction of cancer cells (no risk of re-
currence), not excluded in the first option. The histologic-
al examination of a piece of ovarian tissue before freezing
is always requested in order to exclude micro metastases.
However, reports in the literature mention the risk of can-
cer recurrence after re-transplantation even in the case of
negative histological examination [10].
Our recommendations concerning pre-existing conditions
for OTC are depicted in table 2.
Very often, OTC is indicated in patients with breast cancer
or lymphoma [11–14]. Orthotopic transplantation clearly
outmatches heterotopic transplantation. So far, 18 births
after re-transplantation have been reported worldwide [15].
As one spontaneous pregnancy/live birth has been reported
after subcutaneous transplantation of ovarian tissue to a
woman with a hormonal profile of complete ovarian insuf-
ficiency [16], it has yet to be proven that the reported ba-
bies were really conceived from the orthotopically trans-
planted and not from the residual ovarian tissue.
OTC and transplantation is still an experimental technique
and many open questions remain, as the exact site of trans-
plantation, the risks of relapse, etc. The success depends on
the correct indication of OTC, the age of the patient, the
technique of cryopreservation and the surgical technique of
transplantation.
Agonists of Gonadotrophin Releasing Hormones
(GnRHa)
After a transitory flare-up, GnRHa lead to gonadal sup-
pression. The mechanism of action is that inhibition of
the pituitary-gonadal axis inhibits temporally follicular de-
velopment [17]. However, there is no clear evidence that
GnRHa are efficient at preserving ovarian function after
chemotherapy [18], as existing prospective randomised are
inconclusive. There are even theories that GnRHa could be
harmful during chemotherapy because GnRH receptors are
expressed in up to 50% of ovarian and BC but not on prim-
ordial follicles [19, 20].
In two prospective randomised studies, GnRHa did not
preserve gonadal function [21, 22]. However, two recent
randomised studies on BC patients showed a benefit of
GnRHa in ovarian protection [23, 24]. A meta-analysis,
only including prospective randomised studies, showed an
improved outcome after GnRHa [25]. Another meta-ana-
lysis, including 11 prospective studies (three randomised
and eight non-randomised), showed also a better outcome
after GnRHa [26]. However, a separate analysis of the
three randomised studies did not show a protective effect
of GnRHa any more [27]. Further randomised controlled
studies are under way.
An important advantage of GnRHa is the prevention of
uterine haemorrhage in the case of severe thrombocyt-
Table 2: Conditions that need to be fulfilled before cryopreservation of ovarian tissue.
Ovarian micro metastases are reasonably excluded by histological examination of samples.
Time frame of at least 3 days.
Health status of the patient allows anaesthesia and operation.
Planned cytotoxic therapy is known to induce a premature ovarian failure.
Age of the patient <35 years.
The chance of having a pregnancy with this ovarian tissue has to be weighed with the chance of having a spontaneous pregnancy after recovery.
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openia induced by chemotherapy by inhibiting menstru-
ations.
Transposition of the ovaries
This surgical technique consists of fixing the ovaries as
far as possible out of the pelvis in case pelvic irradiation.
By laparoscopy, the ovaries are mobilised, tagged with a
clip and fixed cranio-laterally [28]. Ovulatory cycles can be
achieved in up to 85% of patients below 40 years [29]. In
post-pubertal women, radiation with 2 Gy leads to a loss of
circa 50% of primordial follicles, and a loss of up to 100%
is observed after 15 Gy [30]. Ovaries of pre-pubertal girls
appear more resistant to damage from irradiation [31].
Risks include the common operative risks of a laparoscopy,
chronic pelvic pain, often due to adhesions, which can
mandate an operative revision or due to secondary necroses
of the ovary or ovarial cysts [32].
Radical vaginal trachelectomy
Radical vaginal trachelectomy is an operative procedure
preserving the uterus (see also chapter “Cervical cancer”).
Combination of techniques
Methods of fertility preservation can be combined, i.e.
cryopreservation of gametes/embryos with subsequent
GnRHa.
If the combination of IVF-ICSI with sampling of ovarian
tissue [33] can enhance pregnancy chances or if on the
contrary it hampers spontaneous pregnancy by inducing
premature ovarian failure has to be confirmed in further
follow-up studies.
Recommendations of fertility
preservation approaches in the
various cancer cases
In all cases, an evaluation of the ovarian reserve should
be conducted in order to assess the net benefit that can be
expected from the foreseen fertility preservation measure.
AMH levels and AFC scores indeed predict the ovarian
yield that can be expected from COS [34]. From this will
depend the number of harvested oocytes and in turn the cal-
culated pregnancy chances to be expected from the meas-
ure.
Predicting natural pregnancy chances after chemotherapy
only based on pre-chemotherapy AMH levels is probably
impossible, as of now. However, it may be useful to estim-
ate ovarian function after chemotherapy to have an idea on
the chances of pregnancy without treatment [35, 36].
Breast cancer (BC)
Chemotherapy can interfere with ovarian function. But for-
tunately, especially with the combinations used in recent
years, the chance of spontaneous ovarian function after
chemotherapy for BC is relatively high in women under 40
years of age [37, 38].
In the classical therapeutic sequence – selected in most BC
patients – surgery precedes adjuvant chemotherapy ther-
apy. The recommended time interval between surgery and
chemotherapy (3–6 weeks) normally suffices for conduct-
ing one cycle of COS without delaying the onset of chemo-
therapy. Conversely, when preoperative chemotherapy is
preferred, COS is not advisable, as COS would have to be
conducted while the tumour is still in place. In these cases
OTC (or in vitro maturation) may be envisioned. However,
OTC should be avoided if there is a significant chance of
recovery of ovarian function / spontaneous pregnancy after
chemotherapy.
In addition to oocyte/(pre-) embryo cryopreservation,
GnRHa can be administered in ER-/PR-negative patients
despite of a proven benefit (see above), preferably in the
setting of a clinical trial.
Borderline ovarian tumour and ovarian cancer
Borderline ovarian tumour
Fortunately, 75% of cases are stage FIGO I with a long-
term survival rate of nearly a 100%. In these cases, uni-
lateral ovariectomy can be conducted and the uterus pre-
served. A surgical staging is recommended [39]. After-
wards, pregnancies can occur spontaneously, or ovarian
stimulation can be safely used [40].
In advanced stages, conservative treatment can also be dis-
cussed, but the recurrence rate is high [41].
If a bilateral adnexectomy is required, preservation of the
uterus has to be discussed. With this, oocyte donation later
in life would still remain an option to fulfil the child wish.
Epithelial ovarian cancer
Patients with a stage FIGO IA, grade 1–2 have a 5-year
survival rate of 90–95%. Also in these cases, it can be dis-
cussed performing unilateral ovariectomy (with a full sur-
gical staging) and to preserve the uterus [39].
A regular follow-up is mandatory (clinical examination and
Ca-125 every 3 months, ultrasound every 6 months, during
3 years). Surgery after completion of the child wish should
be considered.
Non-epithelial ovarian cancer
The prognosis for these tumours is mostly good. In general,
depending on the stage of the disease, they are cured after
conservative surgery and adjuvant therapy.
Ovarian stimulation
In the nineties, there was a big fear that ovarian stimulation
could enhance the risk of ovarian cancer [42]. Fortunately,
these data have not been confirmed and newer data are
quite reassuring [43, 44].
Cervical cancer
In FIGO stage IA1 and absence of lympho-vascular space
invasion, conisation in sano may be sufficient, although
standard therapy includes total hysterectomy.
In FIGO stage IA2 or IB1 with a tumour size of 2 cm or
less (exceptionally until 3 cm) and negative regional lymph
nodes, radical trachelectomy (ablation of the cervix and
the parametria and conservation of the corpus uteri and the
ovaries) with full pelvic lymph node dissection can be pro-
posed.
Lympho-vascular space invasion is not a contraindication;
however, the risk of recurrence is slightly increased. In all
cases, a multidisciplinary evaluation (pathologist, gynaeco-
logist, radiotherapist and oncologist) is warranted.
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Before trachelectomy, the size of the lesion, the level of
the cervical canal, and the distance between the superior
pole of the lesion and the uterine isthmus have to be evalu-
ated by Magnetic Resonance Imaging (MRI). In about 10%
of the cases, lymph node or parametrical invasion is dia-
gnosed only intra-operatively and trachelectomy has to be
abandoned.
The oncologic results after trachelectomy are similar as
compared to the traditional radical surgery (Wertheim); re-
currence rates are around 5% in 5 years. In about 70%,
pregnancies ensue after trachelectomy. However, late mis-
carriages and prematurity are increased after this procedure
[45–48].
Endometrial cancer
General remarks
In all cases, the diagnosis of endometrial cancer must be re-
vised by an experienced pathologist, for the fear that mis-
diagnosis is possible with dramatic consequences in young
women.
MRI, with a sensitivity of 60–70% (experienced radiolo-
gist), is actually the best exam to evaluate myometrial in-
vasion.
A laparoscopy can be undertaken in order to exclude an
ovarian neoplasia, the risk of a synchronous ovarian tu-
mour being 10–20% in this group of patients.
Because of the low risk of lymph node invasion in patients
with FIGO IA G1-2 (approximately 2–3%), pelvic and/or
para-aortic lymphadenectomy is generally not recommen-
ded.
Standard treatment for atypical hyperplasia is total hys-
terectomy. Early endometrial cancer treatment consists of
hysterectomy and bilateral adnexectomy.
Conservative treatment in atypical hyperplasia and
endometrial cancer
Only in cases of atypical hyperplasia and stages FIGO
IA grade 1 (endometrioid type), a conservative manage-
ment can be discussed. It comprises the application of sys-
temic high dose progestins. Mean time of response varies
between 4 to 8 months, requiring rigorous monitoring with
biopsies every 3–4 months. There are no clear criteria to
define the optimal duration of treatment [49]. Treatment
has to be followed by hysteroscopy and histological exam-
ination of the endometrium before planning a pregnancy.
As soon as the desired family size is achieved, standard
treatment is proposed.
Acute leukaemia
Healing rates of acute leukaemia vary between 75% (low
risk) and 5–15% (high risk). Treatments usually require ag-
gressive chemotherapy with a high systemic toxicity. Risk
of amenorrhea and persistent infertility may be low after
standard chemotherapy (<15%), but is very high if allo-
transplantation or total body irradiation (TBI) is admin-
istered (>90%) [50].
The major concern is the fact that acute leukaemia is a
therapeutic emergency precluding the possibility of ovarian
stimulation. Ovarian tissue transplantation is contraindic-
ated because of the risk of re-implanting cancer cells [51,
10]. Thus, today, the possibilities of fertility preservation
are unfortunately limited. However, should IVM of prim-
ordial follicles be technically possible in the future, OTC
could perhaps be reconsidered.
Lymphoma
The risk of definitive infertility after a conventional first
line treatment for Hodgkin or Non-Hodgkin Lymphoma is
low. Fertility preservation is generally not indicated in the
case of treatment with ABVD or R-CHOP [52, 53]. Ovari-
an tissue removal, especially if it is extensive, could even
be contra-indicated in these cases because it could decrease
the chances of spontaneous pregnancy after recovery.
Patients presenting high-risk Hodgkin Lymphoma and
treated with a more intensive regimen like BEACOPP have
a risk of long-term infertility of about 50% [54]. Fertility
preservation methods should therefore be proposed. Addi-
tionally, some of these patients may also need radiotherapy
of the pelvis; a pre-therapeutic oophoropexy may be indic-
ated.
Special situations: relapses, allo/auto-transplantation
Patients presenting refractory or relapsed lymphoma are
often candidates for salvage therapies, consisting of poly-
chemotherapies with alkylating agents at high dosage,
sometimes including TBI and frequently followed by auto-
logous/allogenic stem cell transplantation. As the risk of in-
fertility in these cases is very high (90%), fertility preser-
vation methods should be discussed before starting salvage
therapy.
GnRHa during chemotherapy
Studies have given contradictory results: GnRHa in com-
bination with a BEACOPP regimen has been reported to be
beneficial [55, 56], but these observations were not consist-
ent in other trials [21, 22, 57]. Other prospective random-
ised studies are under way.
Paediatric Onco-Haematology
Due to the amelioration of oncologic treatments in the last
40 years, almost 80% of children who currently receive a
diagnosis of cancer become long term survivors. Unfortu-
nately, many treatments for childhood cancer are toxic for
the gonads and 15% of the children will have a comprom-
ised reproductive function.
In the case of treatments with high infertility risks (high
dose alkylating agents, TBI, bilateral ovarian surgery) fer-
tility preservation has to be discussed with the multidiscip-
linary team [57, 59, 60]. A written informed consent (par-
ents and possibly the child) is recommended.
Oncologic situations indicating discussion of fertility pre-
servation are acute lymphoblastic and myeloblastic leuk-
aemia, solid tumours and lymphomas (i.e. Wilms tumour,
neuroblastoma, rhabdomyosarcoma, Hodgkin’s disease).
In certain non-oncologic diseases (myelodysplastic syn-
dromes, severe aplastic anaemia, primary immunodefi-
ciency diseases and severe haemoglobinopathia), haema-
topoietic stem cell transplantation has also to be proposed.
As this procedure requires conditioning regimen with
highly gonadotoxic (alkylating) agents, fertility preserva-
tion has to be considered also in non-oncologic situations.
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Pre-pubertal girls
OTC prior to sterilising treatments is the only option. After
a multidisciplinary consensus, OTC should be discussed
with the girl and her parents. While OTC is still experi-
mental, research is very active in this field. It is important
to keep in mind that while paediatric patients today will
wish a pregnancy in 10 to 20 years or even more, many of
the technical problems might actually be resolved by that
time.
Post-pubertal girls
While cryopreservation of mature oocytes after ovarian
stimulation could be offered in certain non-oncologic
cases, this option is rarely possible in oncologic situations
because chemotherapy has to be initiated immediately.
OTC prior to cytotoxic treatment can be proposed. Ovarian
protection during chemotherapy by GnRHa is still debated,
but often proposed.
Pre-pubertal boys
As the production of spermatozoa begins at puberty, it is
not possible to obtain sperm before the age of 12–13 years.
The cryopreservation of immature testicular tissue is an ex-
perimental technique, only few laboratories in the world
perform this approach and only in a research setting [61].
Post-pubertal boys
Sperm collection followed by cryopreservation is pro-
posed.
Conclusion
Due to progresses in oncology, survival rates of cancer pa-
tients (children and adults) have been constantly improv-
ing. Hence, the reproductive future of these patients needs
to be addressed carefully. Techniques of fertility preserva-
tion exist and must be discussed beforehand, taking into
consideration the various cancer treatments, the time avail-
able, the general condition, the patients’ ages and marital
projects as well as their own personal wishes. Crucial to the
good quality of the care provided is the establishment of
a close functional collaboration between the primary onco-
logy team and reproductive medicine specialists for always
offering the best options possible.
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